- Home
- NXL vs NCRA Comparison
NXL vs NCRA Comparison
Compare NXL & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- NCRA
- Stock Information
- Founded
- NXL 2010
- NCRA 2002
- Country
- NXL United States
- NCRA Taiwan
- Employees
- NXL N/A
- NCRA N/A
- Industry
- NXL Medical Specialities
- NCRA Farming/Seeds/Milling
- Sector
- NXL Health Care
- NCRA Consumer Staples
- Exchange
- NXL Nasdaq
- NCRA Nasdaq
- Market Cap
- NXL 10.0M
- NCRA 11.7M
- IPO Year
- NXL 2022
- NCRA N/A
- Fundamental
- Price
- NXL $2.87
- NCRA $0.88
- Analyst Decision
- NXL Hold
- NCRA
- Analyst Count
- NXL 1
- NCRA 0
- Target Price
- NXL N/A
- NCRA N/A
- AVG Volume (30 Days)
- NXL 377.2K
- NCRA 17.1K
- Earning Date
- NXL 03-26-2025
- NCRA 01-01-0001
- Dividend Yield
- NXL N/A
- NCRA N/A
- EPS Growth
- NXL N/A
- NCRA N/A
- EPS
- NXL N/A
- NCRA N/A
- Revenue
- NXL $162,078.00
- NCRA $20,483,694.00
- Revenue This Year
- NXL $56.86
- NCRA N/A
- Revenue Next Year
- NXL $167.44
- NCRA N/A
- P/E Ratio
- NXL N/A
- NCRA N/A
- Revenue Growth
- NXL 26.00
- NCRA N/A
- 52 Week Low
- NXL $0.30
- NCRA $0.70
- 52 Week High
- NXL $4.49
- NCRA $2.09
- Technical
- Relative Strength Index (RSI)
- NXL 42.81
- NCRA 46.85
- Support Level
- NXL $2.80
- NCRA $0.80
- Resistance Level
- NXL $3.54
- NCRA $0.89
- Average True Range (ATR)
- NXL 0.38
- NCRA 0.06
- MACD
- NXL -0.02
- NCRA -0.00
- Stochastic Oscillator
- NXL 14.53
- NCRA 46.84
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.